Claims for Patent: 10,456,472

Summary for Patent: 10,456,472

Title:	Phenylalkylcarboxylic acid delivery agents
Abstract:	The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
Inventor(s):	Gschneidner; David (Roseland, NJ), Pusztay; Stephen V. (Orchard Park, NY)
Assignee:	EMISPHERE TECHNOLOGIES, INC. (Roseland, NJ)
Application Number:	15/198,392
Patent Claims:	1. A composition comprising: (A) a biologically active agent; and (B) a delivery agent compound selected from 3-(3-phenoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 5-(4-ethylphenyl)pentanoic acid, and pharmaceutically acceptable salts thereof. 2. The composition of claim 1, wherein the delivery agent compound is 3-(3-phenoxyphenyl)propanoic acid, or a pharmaceutically acceptable salt thereof. 3. The composition of claim 1, wherein the delivery agent compound is 4-(4-ethylphenyl)butanoic acid, or a pharmaceutically acceptable salt thereof. 4. The composition of claim 1, wherein the delivery agent compound is 5-(4-ethylphenyl)pentanoic acid, or a pharmaceutically acceptable salt thereof. 5. The composition of claim 1, wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof. 6. The composition of claim 1, wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, glucagon, interferons, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; gallium or gallium salts; glucagons; zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, caspofungin acetate, CPHPC, siRNA and any combination thereof. 7. The composition of claim 1, further comprising at least one enzyme inhibitor. 8. The composition of claim 1, wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, heparin, recombinant human growth hormone, glucagon, caspofungin acetate, calcitonin, PTH, zanamivir, erythropoietin, analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof. 9. A method of preparing pharmaceutical composition, comprising mixing a delivery agent compound selected from 3-(3-phenoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 5-(4-ethylphenyl)pentanoic acid, and pharmaceutically acceptable salts thereof, and a biologically active agent. 10. The method of claim 9, wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof. 11. The method of claim 9, wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, glucagon, interferons, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; gallium or gallium salts; glucagons; zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, caspofungin acetate, CPHPC, siRNA and any combination thereof. 12. A dosage unit form comprising: (A) a delivery agent compound selected from 3-(3-phenoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 5-(4-ethylphenyl)pentanoic acid, and pharmaceutically acceptable salts thereof; (B) a biologically active agent; and (C) (a) an excipient; (b) a diluent; (c) a disintegrant; (d) a lubricant; (e) a plasticizer; (f) a colorant; (g) an enzyme inhibitor; (h) a dosing vehicle; or (i) any combination thereof. 13. The dosage unit form of claim 12, wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof. 14. The dosage unit form of claim 12, wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, interferons, glucagon, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor, insulin-like growth factor-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine, parathyroid hormone, fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; gallium or gallium salts; glucagons, zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, capsofungin acetate, CPHPC, SiRNA and any combination thereof. 15. The dosage unit form of claim 12, wherein the biologically active agent is selected from the group consisting of insulin, leutenizing-hormone releasing hormone, heparin, recombinant human growth hormone, glucagon, caspofungin acetate, calcitonin, parathyroid hormone, zanamivir, erythropoietin, and any combination thereof. 16. The dosage unit form of claim 12, wherein the dosage unit form is a tablet, a capsule, a powder, or a liquid. 17. The dosage unit form of claim 12, wherein the dosing vehicle is a liquid selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof. 18. A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering to the animal the composition of claim 1. 19. The method of claim 18, wherein the composition is administered intranasally, sublingually, intraduodenally, subcutaneously, buccally, intracolonicly, rectally, vaginally, muco sally, pulmonary, transdermally, intradermally, parenterally, intravenously, intramuscularly, via the ocular system, or by traversing the blood-brain barrier. 20. The method of claim 18, wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or any combination thereof. 21. The method of claim 18, wherein the composition is administered orally.

Details for Patent 10,456,472

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2027-02-08
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2027-02-08
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2027-02-08
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2027-02-08
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2027-02-08
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	06/25/1991		2027-02-08
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	06/01/2018		2027-02-08